Zai Lab Limited
Zai Lab Limited is a biopharmaceutical company based in Shanghai, China, that focuses on the development and commercialization of innovative medicines. Founded in 2014 by Samantha Du, the company has quickly become a key player in the Chinese biotech industry, with a commitment to bringing novel therapies to patients in China and beyond.
Zai Lab has a robust pipeline of drug candidates covering various therapeutic areas, including oncology, autoimmune diseases, and infectious diseases. The company collaborates with global biopharmaceutical companies and conducts in-house research and development to bring cutting-edge treatments to patients in China.
Zai Lab's commitment to innovation and its focus on addressing unmet medical needs have garnered attention from investors and stakeholders. The company's growth has been bolstered by successful clinical trial results and regulatory milestones, demonstrating its potential to become a major player in the biotech industry.
As a publicly traded company, Zai Lab went public on the NASDAQ stock exchange in 2017 under the ticker symbol "ZLAB." The IPO provided the company with the necessary capital to advance its drug development programs and expand its commercialization efforts.
Founded: 2013
Headquarters: Shanghai, China
Twitter: https://twitter.com/ZaiLab_Global
Website: https://www.zailaboratory.com/
